Six weeks after Rwanda-backed rebels captured the eastern Congolese cities of Goma and Bukavu, the region is facing a setback ...

The Eastern Democratic Republic of the Congo is suffering a severe setback in its fight against the Mpox outbreak, six weeks ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

AP Hospitals across eastern Congo that were once at the forefront of the country’s response to the mpox outbreak are facing a setback in detecting the disease and offering treatment following the ...

Dr. Alex Isakov offers updates and insights for EMS professionals on navigating the infectious disease landscape ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...

Nurses are administering medicine to Mpox patients at a tent in Kabare, Democratic Republic of the Congo, as the area ...

The two confirmed infected individuals have symptoms such as rash, fever, and headache, as well as pain in the body and ...

In eastern Congo, mpox detection and treatment face setbacks amid a rebel offensive backed by Rwanda. Hospitals suffer from ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...